Gene · 7030
Papers3,398
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
301 to 320 of 3,398
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Perivascular epithelioid cell neoplasm (PEComa) harboring TFE3 gene rearrangements in a patient with Lynch syndrome. | Gastroenterol Hepatol | 2025 | 38852779 | PubTator, text mining | PubMed |
| TFE3 rearranged epithelioid hemangioendothelioma of the lymph node: A rare primary presentation of vascular tumor. | Indian J Pathol Microbiol | 2025 | 38563707 | PubTator, text mining | PubMed |
Correction: Qin et al. Production and Stabilization of Specific Upregulated Long Noncoding RNA HOXD-AS2 in Glioblastomas Are Mediated by TFE3 and miR-661, Respectively. Int. J. Mol. Sci. 2022, 23, 2828. | Int J Mol Sci | 2024 | 39796287 | PubTator, text mining | PubMed |
| Upregulation of GSTP1 mediated by chimeric TFE3 promotes TFE3-tRCC progression by targeting JNK signaling pathway. | World J Surg Oncol | 2024 | 39736746 | PubTator, text mining | PubMed |
| ARID2 Deficiency Enhances Tumor Progression via ERBB3 Signaling in TFE3-Rearranged Renal Cell Carcinoma. | Curr Issues Mol Biol | 2024 | 39727945 | PubTator, text mining | PubMed |
| Management of translocation carcinomas of the kidney. | Transl Cancer Res | 2024 | 39697715 | PubTator, text mining | PubMed |
| Hexamethylene amiloride induces lysosome-mediated cell death in multiple myeloma through transcription factor E3. | Cell Death Discov | 2024 | 39695174 | PubTator, text mining | PubMed |
| Endometrioid adenocarcinoma combined with TFE3-rearranged renal cell carcinoma: A case report. | Asian J Surg | 2024 | 39674799 | PubTator, text mining | PubMed |
| Case report: A rare low-grade fumarate hydratase-deficient renal cell carcinoma. | Front Oncol | 2024 | 39659780 | PubTator, text mining | PubMed |
| The ATAC complex represses the transcriptional program of the autophagy-lysosome pathway via its E3 ubiquitin ligase activity. | Cell Rep | 2024 | 39643968 | PubTator, text mining | PubMed |
| Metastatic Extra Renal (Adrenal) TFE3 Translocation-Associated Renal Cell Carcinoma. | Cureus | 2024 | 39629290 | PubTator, text mining | PubMed |
| The nutrient-sensing Rag-GTPase complex in B cells controls humoral immunity via TFEB/TFE3-dependent mitochondrial fitness. | Nat Commun | 2024 | 39580479 | PubTator, text mining | PubMed |
| Massive simultaneous hepatic and renal perivascular epithelioid cell tumor benefitted from surgery and everolimus treatment: A case report. | World J Gastrointest Surg | 2024 | 39575269 | PubTator, text mining | PubMed |
| Genomic profiling and molecular characterization of non-clear cell renal cell carcinoma: a narrative review from a clinical perspective. | Ther Adv Med Oncol | 2024 | 39563719 | PubTator, text mining | PubMed |
| Clear cell stromal tumor of the lung: Report of 3 cases with emphasis on multifocal tumors. | Pathol Res Pract | 2024 | 39556929 | PubTator, text mining | PubMed |
| TFEB links the cGAS-STING pathway to lysosome biogenesis. | Trends Cell Biol | 2024 | 39547882 | PubTator, text mining | PubMed |
| Correction to "Renal cell carcinoma in the contralateral kidney with TFE3 gene translocation following chemotherapy for childhood nephroblastoma: A case report and literature review". | Clin Case Rep | 2024 | 39525807 | PubTator, text mining | PubMed |
| TFE3-Rearranged Renal Cell Carcinoma With Osseous Metaplasia: A Case Report of a Rare Entity With an Unusual Finding. | Cureus | 2024 | 39502747 | PubTator, text mining | PubMed |
| Exploratory analysis of immunomodulatory factors identifies L1CAM as a prognostic marker in alveolar soft-part sarcoma. | Ther Adv Med Oncol | 2024 | 39502403 | PubTator, text mining | PubMed |
| Primary pulmonary alveolar soft part sarcoma with ASPSCR1-TFE3 gene fusion: Case report and literature review. | Medicine (Baltimore) | 2024 | 39495972 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/7030/papers?page=16